Read by QxMD icon Read

vamsidhar velcheti

Mehdi Alilou, Niha Beig, Mahdi Orooji, Anant Madabhushi, Prabhakar Rajiah, Michael Yang, Robert Gilkeson, Philip Linden, Vamsidhar Velcheti, Sagar Rakshit, Niyoti Reddy, Frank Jacono
PURPOSE: Distinguishing between benign granulmoas and adenocarcinomas is confounded by their similar visual appearance on routine CT scans. Unfortunately, owing to the inability to discriminate these lesions radigraphically, many patients with benign granulomas are subjected to unnecessary surgical wedge resections and biopsies for pathologic confirmation of cancer presence or absence. This suggests the need for improved computerized characterization of these nodules in order to distinguish between these two classes of lesions on CT scans...
March 14, 2017: Medical Physics
Katherine Glass, Alicia M Redden, Nathan A Pennell, James Stevenson, Vamsidhar Velcheti, Emily Van Wagoner, Chad W Cummings, Brian James Bolwell
29 Background: Patient-centered outcomes are important quality metrics of value-based cancer care. For NSCLC, these include chemotherapy administration within 30 days of death and end of life hospitalizations. Nivolumab was initially FDA approved in March 2015 for second-line therapy of squamous NSCLC and subsequently for non-squamous NSCLC. To evaluate the impact of post-approval nivolumab use on patient-centered outcomes, a retrospective review was performed of patients (pts) with metastatic NSLCC receiving nivolumab at TCI main campus and regional centers...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Leah M Pervere, Sagar Rakshit, Alexa B Schrock, Vincent A Miller, Siraj M Ali, Vamsidhar Velcheti
No abstract text is available yet for this article.
November 11, 2016: Clinical Lung Cancer
Mark A Socinski, Joan Schiller, Shaker Dakhil, Shayma Kazmi, Joseph Leach, Sylvia Hu, Sarah M Paul, David S Shames, See Phan, Cindy Yun, Vamsidhar Velcheti
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
Sai-Hong Ignatius Ou, Alexa B Schrock, Eduard V Bocharov, Samuel J Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa Johnson, Barbara J Gitlitz, Jon Chung, Paulo V Campregher, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, James H Suh, Siraj M Ali, Vamsidhar Velcheti
INTRODUCTION: Erb-b2 receptor tyrosine kinase (HER2) transmembrane domain (TMD) mutations (HER2(V659E), HER2(G660D)) have previously been identified in lung adenocarcinomas, but their frequency and clinical significance is unknown. METHODS: We prospectively analyzed 8551 consecutive lung adenocarcinomas using hybrid capture-based comprehensive genomic profiling (CGP) at the request of the individual treating physicians for the purpose of making therapy decisions...
March 2017: Journal of Thoracic Oncology
Charles D Sturgis, Dana Ataya, Benjamin C Calhoun, Vamsidhar Velcheti, Sanjay Mukhopadhyay
No abstract text is available yet for this article.
November 2016: Annals of the American Thoracic Society
Sameep Sehgal, Vamsidhar Velcheti, Sanjay Mukhopadhyay, James K Stoller
A 58-year-old woman with stage 4 adenocarcinoma of the lung being treated with pembrolizumab developed dyspnea, non-productive cough, and a right middle lobe infiltrate. Complete resolution of the infiltrate with cessation of pembrolizumab, initiation of prednisone and no antibiotic therapy suggested drug-associated lung toxicity as the cause. While the programmed death-1 (PD-1) inhibitors -pembrolizumab and nivolumab - have been implicated as a cause of diffuse or multifocal pulmonary infiltrates, the current case represents, to our knowledge, the first instance of a unilobar, focal infiltrate associated with their use...
2016: Respiratory Medicine Case Reports
Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu, Vamsidhar Velcheti
OBJECTIVES: This analysis aimed to evaluate the cost-effectiveness of pembrolizumab compared with docetaxel in patients with previously treated advanced non-squamous cell lung cancer (NSCLC) with PD-L1 positive tumors (total proportion score [TPS] ≥ 50%). The analysis was conducted from a US third-party payer perspective. METHODS: A partitioned-survival model was developed using data from patients from the KEYNOTE 010 clinical trial. The model used Kaplan-Meier (KM) estimates of progression-free survival (PFS) and overall survival (OS) from the trial for patients treated with either pembrolizumab 2 mg/kg or docetaxel 75 mg/m(2) with extrapolation based on fitted parametric functions and long-term registry data...
February 2017: Journal of Medical Economics
Leonard Calabrese, Vamsidhar Velcheti
No abstract text is available yet for this article.
January 2017: Annals of the Rheumatic Diseases
Kurt A Schalper, Daniel Carvajal-Hausdorf, Joseph McLaughlin, Mehmet Altan, Vamsidhar Velcheti, Patricia Gaule, Miguel F Sanmamed, Lieping Chen, Roy S Herbst, David L Rimm
PURPOSE: To determine the expression level, associations, and biological role of PD-L1, IDO-1, and B7-H4 in non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: Using multiplexed quantitative immunofluorescence (QIF), we measured the levels of PD-L1, IDO-1, B7-H4, and different tumor-infiltrating lymphoycte (TIL) subsets in 552 stages I-IV lung carcinomas from two independent populations. Associations between the marker levels, TILs, and major clinicopathologic variables were determined...
July 20, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Vamsidhar Velcheti, Kurt Schalper
Recent success of immunotherapy strategies such as immune checkpoint blockade in several malignancies has established the role of immunotherapy in the treatment of cancer. Cancers use multiple mechanisms to co-opt the host-tumor immune interactions, leading to immune evasion. Our understanding of the host-tumor interactions has evolved over the past few years and led to various promising new therapeutic strategies. This article will focus on the basic principles of immunotherapy, novel pathways/agents, and combinatorial immunotherapies...
2016: American Society of Clinical Oncology Educational Book
Lindsey Martin Goodman, Machelle B Moeller, Abdel-Ghani Azzouqa, Amy E Guthrie, Carole K Dalby, Marc A Earl, Connie Cheng, Nathan A Pennell, Marc Shapiro, Vamsidhar Velcheti, James P Stevenson
PURPOSE: Routine prophylactic pegylated granulocyte colony-stimulating factor (pGCSF) administration for patients receiving chemotherapy regimens associated with low risk (< 10%) for neutropenic fever (LRNF) is not recommended. Inappropriate use of pGCSF increases patient morbidity and health care costs. METHODS: A multidisciplinary team reviewed the charts of patients with non-small-cell lung cancer (NSCLC) at the Taussig Cancer Institute in whom a new chemotherapy regimen was initiated from April through November 2013...
January 2016: Journal of Oncology Practice
Todd Hembrough, Wei-Li Liao, Christopher P Hartley, Patrick C Ma, Vamsidhar Velcheti, Christopher Lanigan, Sheeno Thyparambil, Eunkyung An, Manish Monga, David Krizman, Jon Burrows, Laura J Tafe
BACKGROUND: Crizotinib has antitumor activity in ALK (anaplastic lymphoma receptor tyrosine kinase)-rearranged non-small cell lung cancer (NSCLC). The current diagnostic test for ALK rearrangement is breakapart fluorescence in situ hybridization (FISH), but FISH has low throughput and is not always reflective of protein concentrations. The emergence of multiple clinically relevant biomarkers in NSCLC necessitates efficient testing of scarce tissue samples. We developed an anaplastic lymphoma kinase (ALK) protein assay that uses multiplexed selected reaction monitoring (SRM) to quantify absolute amounts of ALK in formalin-fixed paraffin-embedded (FFPE) tumor tissue...
January 2016: Clinical Chemistry
Joseph McLaughlin, Gang Han, Kurt A Schalper, Daniel Carvajal-Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy Herbst, Patricia LoRusso, David L Rimm
IMPORTANCE: Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable clinical responses in patients with non-small-cell lung cancer (NSCLC). However, current assays for the prognostic and/or predictive role of tumor PD-L1 expression are not standardized with respect to either quantity or distribution of expression. OBJECTIVE: To demonstrate PD-L1 protein distribution in NSCLC tumors using both conventional immunohistochemistry (IHC) and quantitative immunofluorescence (QIF) and compare results obtained using 2 different PD-L1 antibodies...
January 2016: JAMA Oncology
Maria Vassilakopoulou, Margaritis Avgeris, Vamsidhar Velcheti, Vassiliki Kotoula, Theodore Rampias, Kyriakos Chatzopoulos, Christos Perisanidis, Christos K Kontos, Aris I Giotakis, Andreas Scorilas, David Rimm, Clarence Sasaki, George Fountzilas, Amanda Psyrri
PURPOSE: Programmed death-ligand 1 (PD-L1; also known as CD274 or B7-H1) expression represents a mechanism of immune escape for cancer. Our purpose was to characterize tumor PD-L1 expression and associated T-cell infiltration in primary laryngeal squamous cell carcinomas (SCC). EXPERIMENTAL DESIGN: A well-annotated cohort of 260 operable primary laryngeal SCCs [formalin-fixed paraffin-embedded (FFPE) specimens] was morphologically characterized for stromal tumor-infiltrating lymphocytes (TIL), on hematoxylin/eosin-stained whole sections and for PD-L1 mRNA expression by qRT-PCR in FFPE specimens...
February 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Vyshak Alva Venur, Gloria Zhang, Carol Farver, Sanjay Mukhopadhyay, Daniel P Raymond, Vamsidhar Velcheti
We report a case of granular cell tumor (GCT) of the lung with coexistent invasive adenocarcinoma. GCTs are rare tumors and often benign and amenable to local bronchoscopic excision. However, occasionally they are more aggressive and locally infiltrative requiring definitive surgical resection. Our patient had a central and infiltrative GCT, in addition a very small (6 mm) peripheral nodule in the same lobe as the GCT, which after careful examination of the surgical specimen during grossing was found to be an invasive adenocarcinoma...
August 2014: Translational Lung Cancer Research
Kurt A Schalper, Jason Brown, Daniel Carvajal-Hausdorf, Joseph McLaughlin, Vamsidhar Velcheti, Konstantinos N Syrigos, Roy S Herbst, David L Rimm
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are usually measured using subjective methods. Studies suggest that TIL subtypes have independent roles in cancer and that they could support the use of novel immunostimulatory therapies. We simultaneously measured TIL subtypes in non-small cell lung cancer (NSCLC) samples using objective methods and determined their relationship with clinico-pathologic characteristics and survival. METHODS: Using multiplexed quantitative fluorescence (QIF), we measured the levels of CD3, CD8, and CD20 in 552 NSCLC from two independent collections represented in tissue microarrays (YTMA79, n = 202 and YTMA140, n = 350)...
March 2015: Journal of the National Cancer Institute
Sanjay Mukhopadhyay, Nathan A Pennell, Siraj M Ali, Jeffrey S Ross, Patrick C Ma, Vamsidhar Velcheti
Oncogenic rearrangements of the RET gene have recently been described in 1% to 2% of lung adenocarcinomas. We report five cases of RET-rearranged lung adenocarcinoma with an unusual constellation of clinical and histologic features that has not previously been described in tumors with this genomic alteration. The age at diagnosis of the five patients (4F, 1M) ranged from 44 to 77 years. All were never-smokers. Radiologically, four tumors showed lymphangitic spread within the lungs at presentation; three of these had multiple bilateral lung nodules...
November 2014: Journal of Thoracic Oncology
Tanmay Panchabhai, Debabrata Bandyopadhyay, Siva Raja, Sudhish Murthy, Vamsidhar Velcheti, Sanjay Mukhopadhyay, Joseph Cicenia, Sonali Sethi
Bronchology/Interventional Procedures Cases IISESSION TYPE: Affiliate Case Report SlidePRESENTED ON: Monday, October 27, 2014 at 11:00 AM - 12:00 PMINTRODUCTION: Inflammatory Myofibroblastic tumors (IMT) were previously included in the loose term "Inflammatory Pseudotumor." However, the rarity of these tumors makes diagnosis and management fairly challenging. We present an interesting presentation of an endobronchial presentation of IMT.CASE PRESENTATION: An 18-year-old non-smoking female presented with cough and intermittent hemoptysis over a few weeks...
October 1, 2014: Chest
Kurt A Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, David L Rimm
PURPOSE: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1 protein expression may predict response to drugs targeting this pathway. Measurement of PD-L1 protein is limited by the lack of standardized immunohistochemical methods and variable performance of antibodies. Our goal was to correlate PD-L1 mRNA expression with clinical variables in primary breast carcinomas...
May 15, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"